Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Abstract Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the risk of hospitalization/death in high-risk adults. At...

Full description

Bibliographic Details
Main Authors: Julie M. Strizki, Jay A. Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, Jiejun Du, Patricia Carmelitano, Michelle L. Brown, Amanda Paschke, Carisa De Anda
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-11-01
Series:Infectious Diseases and Therapy
Subjects:
Antiviral
COVID-19
Delta
Infectivity
MK-4482
Molnupiravir
Online Access:https://doi.org/10.1007/s40121-023-00891-1

Internet

https://doi.org/10.1007/s40121-023-00891-1

Similar Items